Press Releases

• cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of 90%1,2

• If Approved in the European Union, rADAMTS13 Will Be the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for cTTP

• Positive Opinion Based on Totality of Evidence, Including Results from the First Randomized, Controlled, Open-label, Crossover Phase 3 cTTP Trial

OSAKA, Japan & CAMBRIDGE,... (continue reading...)

• GEMXX recently entered a significant partnership with Latin Energy Partners that has seen the two companies define terms to jointly drill four test wells in a promising geologic formation in a Latin American country
• The partnership is part of GEMXX’s plans to strategically expand its current successful business model, diversifying its business portfolio, and exploring new underground resource opportunities
• Latin America has large tracts and regions of... (continue reading...)

BOSTON, May 31, 2024 /PRNewswire/ -- Expert.ai, the industry leader in providing AI-powered language solutions to enterprises, has been named a Leader in The Forrester Wave™: Document Mining and Analytics Platforms, Q2 2024*. From the original pool of 41 vendors in The Document Mining and Analytics Platforms Landscape, Q1 2024** to the 14 companies evaluated across 25 criteria for the Document Mining and Analytics Platforms Forrester Wave Report, expert.ai received... (continue reading...)

Châtillon, France, May 31, 2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary... (continue reading...)

MINNEAPOLIS--(BUSINESS WIRE)-- Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week. This convention, known for its global reach and influence, provides a... (continue reading...)